The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Felip, E ^a   Vilar, E ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; PACLITAXEL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

EID: 33749619474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl247     Document Type: Article

References (23)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
2. Andre F, Grunenwald O, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol 2000; 18: 2981-2989.
3. Pass HI, Pogrebniak HW, Steinberg SM et al. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis. Ann Thorac Surg 1992; 53: 992-998.
4. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158.
5. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: Definitive analysis of a randomized controlled trial. Lung Cancer 1999; 26: 7-14.
6. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
7. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
8. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1NO), II, and IIIa non-small-cell lung cancer. J Clin Oncoll 2002; 20: 247-253.
9. Mattson KV, Abratt RP, ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: A multinational randomised phase III study. Ann Oncol 2003; 14: 116-122.
10. Berghmans T, Paesmans M, Meert AP et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 2005; 49: 13-23.
11. Betticher DC, Hsu Schmitz SF, Totsch M et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patents with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 2003; 21: 1752-1759.
12. Cappuzzo F, Selvaggi G, Gregorc V et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB nonsmall cell lung carcinoma: An Italian Lung Cancer Project Observational Study. Cancer 2003; 98: 128-134.
13. Van Zandwijk N, Smit EF, Kramer GW et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18: 2658-2664.
14. O'Brien ME, Splinter T, Smit EF et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. An EORTC phase II study (EORTC 08958). Eur J Cancer 2003; 39: 1416-1422.
15. De Marinis F, Nelli F, Migliorino MR et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) non-small cell lung carcinoma: A phase II multicenter study. Cancer 2003; 98: 1707-1715.
16. Garrido P, Rosell R, Torres A et al. Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) as neoadjuvant treatment in stage IIIAN2 and T4N0-1 NSCLC patients. Final results of SLCG phase II trial 9901. Lung Cancer (IASLC Meeting Abstracts) 2005 (abstr 033).
17. Pisters KM, Ginsberg RJ, Giroux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119: 429-439.
18. Pisters K, Vallieres E, Bunn P et al. S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/ carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol (Meeting Abstracts) 2005; 23: LBA7012.
19. Albain KS, Swann RS, Rusch V et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol (Meeting Abstracts) 2005; 23: LBA7014.
20. Van Meerbeeck JP, Kramer G, PE van Schil et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol (Meeting Abstracts) 2005; 23: LBA7015.
21. Mamon HJ, Yeap BY, Janne PA et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005; 23: 1530-1537.
22. Rosell R, Felip E, Taron M et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10: 4215s-4219s.
23. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics 2004; 13: 2443-2449.